Montelukast for Type 2 Diabetes

This trial aims to determine if montelukast, a medication typically used for asthma, can improve kidney and heart health in young people with type 2 diabetes. Researchers seek to discover whether montelukast can limit damage to the kidneys and blood vessels, common issues in diabetes. Participants will receive either montelukast or a placebo (a pill with no active drug) to compare effects. This trial suits young people who have had type 2 diabetes for less than 10 years and are managing their condition but still face challenges with kidney or heart health. As an Early Phase 1 trial, this research focuses on understanding how montelukast works in people, offering participants a chance to contribute to groundbreaking research.

Previous studies have generally shown that montelukast is well-tolerated for conditions like asthma. The FDA has already approved it for asthma treatment, indicating it has passed certain safety checks for that use. Common side effects include headaches and stomach pain, typically mild. Serious side effects are rare. As this trial is in its early phase, researchers are still studying the safety of montelukast for type 2 diabetes in young people. However, its existing approval for asthma offers some reassurance about its overall safety.¹²³⁴⁵

Unlike the standard treatments for type 2 diabetes, which typically include medications like metformin and insulin that target blood sugar levels, Montelukast is unique because it is primarily an asthma medication. Researchers are excited about Montelukast because it may offer a new mechanism of action by addressing inflammation associated with diabetes, potentially improving insulin sensitivity. This different approach could complement existing therapies and offer additional benefits for patients managing type 2 diabetes.

Research has shown that montelukast, a drug often used for asthma, might help with type 2 diabetes by blocking certain substances called cysteinyl leukotrienes. These substances link to inflammation and damage in the kidneys and blood vessels, common issues in diabetes. Early findings suggest that reducing these substances might allow montelukast to protect these organs. In this trial, some participants will receive montelukast to evaluate its potential benefits for managing complications related to type 2 diabetes. Although research on its effects in diabetes continues, the mechanism of montelukast offers a promising possibility for managing these complications.